Stockreport

Entrada Therapeutics Reports Third Quarter 2025 Financial Results

Entrada Therapeutics, Inc.  (TRDA) 
PDF -- Company on track to report ELEVATE-44-201 data from first patient cohort in Q2 2026 -- -- First patient dosed in ELEVATE-45-201 and the Company is on track to report [Read more]